Gufic Biosciences Limited (GUFICBIO.BO) Stock Competitors & Peer Comparison

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SUNPHARMA.NS has a market cap of 4.4T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SUNPHARMA.NS trades at ₹1,863.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SUNPHARMA.NS's P/E ratio is 38.52. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SUNPHARMA.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SUNPHARMA.BO has a market cap of 4.4T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SUNPHARMA.BO trades at ₹1,860.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SUNPHARMA.BO's P/E ratio is 40.38. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SUNPHARMA.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while DIVISLAB.NS trades at ₹6,779.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas DIVISLAB.NS's P/E ratio is 69.76. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check DIVISLAB.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while DIVISLAB.BO trades at ₹6,793.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas DIVISLAB.BO's P/E ratio is 69.73. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check DIVISLAB.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while TORNTPHARM.NS trades at ₹4,461.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas TORNTPHARM.NS's P/E ratio is 69.36. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check TORNTPHARM.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while TORNTPHARM.BO trades at ₹4,448.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas TORNTPHARM.BO's P/E ratio is 69.99. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check TORNTPHARM.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while LUPIN.BO trades at ₹2,338.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas LUPIN.BO's P/E ratio is 24.92. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check LUPIN.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ZYDUSLIFE.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ZYDUSLIFE.NS's P/E ratio is 21.39. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ZYDUSLIFE.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ZYDUSLIFE.BO trades at ₹1,083.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ZYDUSLIFE.BO's P/E ratio is 21.40. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ZYDUSLIFE.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while LUPIN.NS trades at ₹2,338.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas LUPIN.NS's P/E ratio is 20.21. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check LUPIN.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while DRREDDY.NS trades at ₹1,291.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas DRREDDY.NS's P/E ratio is 24.72. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check DRREDDY.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while DRREDDY.BO trades at ₹1,291.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas DRREDDY.BO's P/E ratio is 18.74. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check DRREDDY.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, MANKIND.BO has a market cap of 998.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while MANKIND.BO trades at ₹2,526.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas MANKIND.BO's P/E ratio is 52.33. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check MANKIND.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, MANKIND.NS has a market cap of 997.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while MANKIND.NS trades at ₹2,540.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas MANKIND.NS's P/E ratio is 52.28. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check MANKIND.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AUROPHARMA.BO has a market cap of 862B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AUROPHARMA.BO trades at ₹1,491.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AUROPHARMA.BO's P/E ratio is 25.43. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AUROPHARMA.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AUROPHARMA.NS has a market cap of 861.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AUROPHARMA.NS trades at ₹1,492.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AUROPHARMA.NS's P/E ratio is 24.82. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AUROPHARMA.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, LAURUSLABS.NS has a market cap of 762.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while LAURUSLABS.NS trades at ₹1,435.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas LAURUSLABS.NS's P/E ratio is 85.53. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check LAURUSLABS.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, LAURUSLABS.BO has a market cap of 762.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while LAURUSLABS.BO trades at ₹1,435.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas LAURUSLABS.BO's P/E ratio is 85.57. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check LAURUSLABS.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ALKEM.NS has a market cap of 642.5B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ALKEM.NS trades at ₹5,369.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ALKEM.NS's P/E ratio is 27.91. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ALKEM.NS's ROE of +0.18%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ALKEM.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ALKEM.BO has a market cap of 641.9B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ALKEM.BO trades at ₹5,371.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ALKEM.BO's P/E ratio is 27.91. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ALKEM.BO's ROE of +0.18%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ALKEM.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, GLENMARK.BO has a market cap of 624.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while GLENMARK.BO trades at ₹2,192.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas GLENMARK.BO's P/E ratio is 45.83. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check GLENMARK.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, GLENMARK.NS has a market cap of 624.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while GLENMARK.NS trades at ₹2,193.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas GLENMARK.NS's P/E ratio is 45.82. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check GLENMARK.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SUVENPHAR.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SUVENPHAR.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, IPCALAB.NS has a market cap of 402.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while IPCALAB.NS trades at ₹1,594.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas IPCALAB.NS's P/E ratio is 35.27. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to IPCALAB.NS's ROE of +0.15%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check IPCALAB.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, IPCALAB.BO has a market cap of 402.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while IPCALAB.BO trades at ₹1,599.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas IPCALAB.BO's P/E ratio is 35.23. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to IPCALAB.BO's ROE of +0.15%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check IPCALAB.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AJANTPHARM.NS has a market cap of 383B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AJANTPHARM.NS trades at ₹3,185.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AJANTPHARM.NS's P/E ratio is 36.33. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to AJANTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AJANTPHARM.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AJANTPHARM.BO has a market cap of 382.5B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AJANTPHARM.BO trades at ₹3,191.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AJANTPHARM.BO's P/E ratio is 37.76. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to AJANTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AJANTPHARM.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, JBCHEPHARM.NS has a market cap of 352.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while JBCHEPHARM.NS trades at ₹2,211.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas JBCHEPHARM.NS's P/E ratio is 49.28. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check JBCHEPHARM.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, JBCHEPHARM.BO has a market cap of 351.5B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while JBCHEPHARM.BO trades at ₹2,204.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas JBCHEPHARM.BO's P/E ratio is 49.19. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check JBCHEPHARM.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, EMCURE.NS has a market cap of 338B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while EMCURE.NS trades at ₹1,793.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas EMCURE.NS's P/E ratio is 36.55. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check EMCURE.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, WOCKPHARMA.NS has a market cap of 326.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while WOCKPHARMA.NS trades at ₹2,016.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas WOCKPHARMA.NS's P/E ratio is 154.11. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check WOCKPHARMA.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, WOCKPHARMA.BO has a market cap of 326.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while WOCKPHARMA.BO trades at ₹2,014.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas WOCKPHARMA.BO's P/E ratio is 153.86. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check WOCKPHARMA.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check PEL.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, NEULANDLAB.BO has a market cap of 222.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while NEULANDLAB.BO trades at ₹17,223.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas NEULANDLAB.BO's P/E ratio is 61.06. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check NEULANDLAB.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, NEULANDLAB.NS has a market cap of 222.5B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while NEULANDLAB.NS trades at ₹17,230.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas NEULANDLAB.NS's P/E ratio is 61.02. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check NEULANDLAB.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ASTRAZEN.NS has a market cap of 210.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ASTRAZEN.NS trades at ₹8,567.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ASTRAZEN.NS's P/E ratio is 112.70. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ASTRAZEN.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, PPLPHARMA.NS has a market cap of 210.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while PPLPHARMA.NS trades at ₹158.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas PPLPHARMA.NS's P/E ratio is -64.59. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to PPLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check PPLPHARMA.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, PPLPHARMA.BO has a market cap of 210.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while PPLPHARMA.BO trades at ₹159.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas PPLPHARMA.BO's P/E ratio is -64.55. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check PPLPHARMA.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ASTRAZEN.BO has a market cap of 210B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ASTRAZEN.BO trades at ₹8,586.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ASTRAZEN.BO's P/E ratio is 112.39. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ASTRAZEN.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ERIS.NS has a market cap of 200.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ERIS.NS trades at ₹1,436.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ERIS.NS's P/E ratio is 31.98. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ERIS.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ERIS.BO has a market cap of 200.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ERIS.BO trades at ₹1,433.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ERIS.BO's P/E ratio is 31.92. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ERIS.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, GRANULES.NS has a market cap of 195B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while GRANULES.NS trades at ₹778.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas GRANULES.NS's P/E ratio is 32.16. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check GRANULES.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, GRANULES.BO has a market cap of 194.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while GRANULES.BO trades at ₹779.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas GRANULES.BO's P/E ratio is 34.94. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check GRANULES.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, CAPLIPOINT.BO has a market cap of 190.5B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while CAPLIPOINT.BO trades at ₹2,536.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas CAPLIPOINT.BO's P/E ratio is 29.77. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check CAPLIPOINT.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, CAPLIPOINT.NS has a market cap of 190.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while CAPLIPOINT.NS trades at ₹2,535.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas CAPLIPOINT.NS's P/E ratio is 29.74. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check CAPLIPOINT.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, NATCOPHARM.BO has a market cap of 159.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while NATCOPHARM.BO trades at ₹885.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas NATCOPHARM.BO's P/E ratio is 10.34. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check NATCOPHARM.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, NATCOPHARM.NS has a market cap of 159.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while NATCOPHARM.NS trades at ₹884.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas NATCOPHARM.NS's P/E ratio is 11.23. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check NATCOPHARM.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, COHANCE.BO has a market cap of 156.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while COHANCE.BO trades at ₹407.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas COHANCE.BO's P/E ratio is 86.88. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to COHANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check COHANCE.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, COHANCE.NS has a market cap of 155.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while COHANCE.NS trades at ₹403.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas COHANCE.NS's P/E ratio is 86.91. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check COHANCE.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, JUBLPHARMA.NS has a market cap of 154.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while JUBLPHARMA.NS trades at ₹956.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas JUBLPHARMA.NS's P/E ratio is 38.81. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check JUBLPHARMA.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, JUBLPHARMA.BO has a market cap of 154.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while JUBLPHARMA.BO trades at ₹954.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas JUBLPHARMA.BO's P/E ratio is 38.83. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check JUBLPHARMA.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, APLLTD.NS has a market cap of 150B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while APLLTD.NS trades at ₹780.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas APLLTD.NS's P/E ratio is 22.24. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to APLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check APLLTD.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, APLLTD.BO has a market cap of 149.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while APLLTD.BO trades at ₹781.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas APLLTD.BO's P/E ratio is 22.17. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check APLLTD.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check GLS.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check GLS.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ALIVUS.NS has a market cap of 131.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ALIVUS.NS trades at ₹1,077.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ALIVUS.NS's P/E ratio is 23.33. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ALIVUS.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ALIVUS.BO has a market cap of 131.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ALIVUS.BO trades at ₹1,076.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ALIVUS.BO's P/E ratio is 23.31. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ALIVUS.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, VIYASH.NS has a market cap of 111.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while VIYASH.NS trades at ₹271.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas VIYASH.NS's P/E ratio is 63.58. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check VIYASH.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check CAPPL.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SHILPAMED.NS has a market cap of 107.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SHILPAMED.NS trades at ₹547.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SHILPAMED.NS's P/E ratio is 44.36. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SHILPAMED.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, PGHL.BO has a market cap of 104.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while PGHL.BO trades at ₹6,300.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas PGHL.BO's P/E ratio is 31.81. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check PGHL.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, PGHL.NS has a market cap of 103.6B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while PGHL.NS trades at ₹6,309.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas PGHL.NS's P/E ratio is 31.73. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check PGHL.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, STAR.NS has a market cap of 102.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while STAR.NS trades at ₹1,117.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas STAR.NS's P/E ratio is 18.42. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check STAR.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, STAR.BO has a market cap of 102.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while STAR.BO trades at ₹1,114.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas STAR.BO's P/E ratio is 18.38. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check STAR.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SUDEEPPHRM.NS has a market cap of 95.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SUDEEPPHRM.NS trades at ₹832.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SUDEEPPHRM.NS's P/E ratio is 56.69. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, GUFICBIO.BO is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SUDEEPPHRM.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AKUMS.NS has a market cap of 92.6B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AKUMS.NS trades at ₹617.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AKUMS.NS's P/E ratio is 36.32. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AKUMS.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SPARC.BO has a market cap of 77.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SPARC.BO trades at ₹238.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SPARC.BO's P/E ratio is 4.97. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SPARC.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SPARC.NS has a market cap of 77.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SPARC.NS trades at ₹238.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SPARC.NS's P/E ratio is 4.98. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SPARC.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, FDC.NS has a market cap of 63.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while FDC.NS trades at ₹403.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas FDC.NS's P/E ratio is 22.52. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check FDC.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, FDC.BO has a market cap of 63.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while FDC.BO trades at ₹403.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas FDC.BO's P/E ratio is 22.49. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check FDC.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AARTIPHARM.NS has a market cap of 62.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AARTIPHARM.NS trades at ₹678.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AARTIPHARM.NS's P/E ratio is 35.96. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AARTIPHARM.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AARTIPHARM.BO has a market cap of 62.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AARTIPHARM.BO trades at ₹682.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AARTIPHARM.BO's P/E ratio is 35.94. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AARTIPHARM.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SUVEN.BO has a market cap of 60.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SUVEN.BO trades at ₹265.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SUVEN.BO's P/E ratio is -21.78. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SUVEN.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SUVEN.NS has a market cap of 60.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SUVEN.NS trades at ₹265.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SUVEN.NS's P/E ratio is -22.09. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SUVEN.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, INNOVACAP.NS has a market cap of 54.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while INNOVACAP.NS trades at ₹941.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas INNOVACAP.NS's P/E ratio is 38.62. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check INNOVACAP.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SHILPAMED.BO has a market cap of 53.9B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SHILPAMED.BO trades at ₹548.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SHILPAMED.BO's P/E ratio is 44.38. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SHILPAMED.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, BLISSGVS.BO has a market cap of 51.5B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while BLISSGVS.BO trades at ₹476.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas BLISSGVS.BO's P/E ratio is 40.52. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to BLISSGVS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check BLISSGVS.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, BLISSGVS.NS has a market cap of 51.4B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while BLISSGVS.NS trades at ₹475.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas BLISSGVS.NS's P/E ratio is 40.46. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to BLISSGVS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check BLISSGVS.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SEQUENT.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SEQUENT.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ORCHPHARMA.NS has a market cap of 49.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ORCHPHARMA.NS trades at ₹958.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ORCHPHARMA.NS's P/E ratio is 239.38. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ORCHPHARMA.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, ORCHPHARMA.BO has a market cap of 49.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while ORCHPHARMA.BO trades at ₹960.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas ORCHPHARMA.BO's P/E ratio is 241.25. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check ORCHPHARMA.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, GUJTHEM.NS has a market cap of 41.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while GUJTHEM.NS trades at ₹402.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas GUJTHEM.NS's P/E ratio is 89.61. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check GUJTHEM.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, IOLCP.BO has a market cap of 38.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while IOLCP.BO trades at ₹130.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas IOLCP.BO's P/E ratio is 27.77. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check IOLCP.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, IOLCP.NS has a market cap of 38.2B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while IOLCP.NS trades at ₹131.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas IOLCP.NS's P/E ratio is 27.76. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check IOLCP.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, RPGLIFE.BO has a market cap of 37.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while RPGLIFE.BO trades at ₹2,325.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas RPGLIFE.BO's P/E ratio is 32.69. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check RPGLIFE.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, RPGLIFE.NS has a market cap of 37.7B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while RPGLIFE.NS trades at ₹2,339.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas RPGLIFE.NS's P/E ratio is 32.73. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check RPGLIFE.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, GUFICBIO.NS has a market cap of 35.6B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while GUFICBIO.NS trades at ₹360.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas GUFICBIO.NS's P/E ratio is 55.51. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check GUFICBIO.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, NOVARTIND.NS has a market cap of 34.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while NOVARTIND.NS trades at ₹1,497.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas NOVARTIND.NS's P/E ratio is 36.82. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check NOVARTIND.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, NOVARTIND.BO has a market cap of 34.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while NOVARTIND.BO trades at ₹1,461.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas NOVARTIND.BO's P/E ratio is 36.74. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check NOVARTIND.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AARTIDRUGS.BO has a market cap of 33.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AARTIDRUGS.BO trades at ₹375.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AARTIDRUGS.BO's P/E ratio is 17.37. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AARTIDRUGS.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, AARTIDRUGS.NS has a market cap of 33.8B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while AARTIDRUGS.NS trades at ₹376.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas AARTIDRUGS.NS's P/E ratio is 17.35. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check AARTIDRUGS.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, UNICHEMLAB.BO has a market cap of 31.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while UNICHEMLAB.BO trades at ₹447.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas UNICHEMLAB.BO's P/E ratio is 12.43. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check UNICHEMLAB.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, UNICHEMLAB.NS has a market cap of 31.3B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while UNICHEMLAB.NS trades at ₹448.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas UNICHEMLAB.NS's P/E ratio is 12.40. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check UNICHEMLAB.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, MOREPENLAB.BO has a market cap of 27.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while MOREPENLAB.BO trades at ₹49.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas MOREPENLAB.BO's P/E ratio is 27.69. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to MOREPENLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check MOREPENLAB.BO's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SOLARA.NS has a market cap of 27.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SOLARA.NS trades at ₹588.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SOLARA.NS's P/E ratio is -329.30. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, GUFICBIO.BO is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SOLARA.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, MOREPENLAB.NS has a market cap of 27.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while MOREPENLAB.NS trades at ₹50.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas MOREPENLAB.NS's P/E ratio is 28.61. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to MOREPENLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check MOREPENLAB.NS's competition here

GUFICBIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUFICBIO.BO stands at 35.6B. In comparison, SOLARA.BO has a market cap of 27.1B. Regarding current trading prices, GUFICBIO.BO is priced at ₹361.40, while SOLARA.BO trades at ₹574.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUFICBIO.BO currently has a P/E ratio of 55.63, whereas SOLARA.BO's P/E ratio is -339.16. In terms of profitability, GUFICBIO.BO's ROE is +0.10%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, GUFICBIO.BO is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for GUFICBIO.BO.Check SOLARA.BO's competition here